Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Plans to Reimburse Coronavirus Tests: Health Minister
February 26, 2020
- Japan Adopts Basic Plan against Novel Coronavirus
February 26, 2020
- Japan Approves Label Expansions for Rozlytrek, Alecensa and More
February 25, 2020
- MHLW Has to Decide Which Bureau Will Lead Formulary Push: Pharmacy Officer
February 21, 2020
- AMED to Fund Development of Coronavirus Diagnostics, Treatments, and Vaccines by NIID, Univ. of Tokyo
February 21, 2020
- Japan Panel to Review J-TEC’s Cell Product, Zolgensma on Feb. 26; Orphan Status for Luxturna Also Up for Discussion
February 20, 2020
- MHLW Looking to Build an “Integrated Pre- to Post-Marketing Assessment System”: Safety Division Chief
February 20, 2020
- MHLW Panel Backs Approval of Sakigake-Designated BNCT Radiation Therapy System
February 20, 2020
- 6 APIs Including Inebilizumab Designated as Orphan Drugs: MHLW
February 19, 2020
- Authorized Generics for Memary, Celecox among Approval List towards June Listing
February 18, 2020
- MHLW Panel to Review Nippon Shinyaku’s Oligonucleotide DMD Drug, Latuda and More on Feb. 28
February 18, 2020
- Japan OKs Edirol Generics towards June Listing, First Gx Entries for 13 Other Drugs Too
February 17, 2020
- Zolgensma Up for Japan Advisory Panel Meeting on Feb. 26, Listing Expected as Early as May
February 17, 2020
- MHLW to Weigh All-Year Invitation for Sakigake Requests: Top Pharmacy Officer
February 14, 2020
- Council Backs Public Knowledge-Based Application for Additional Indication for Novartis’ Sandostatin
February 14, 2020
- Enhertu, BNCT, Tepotinib and More Up for MHLW Panel Review; March Approval Eyed
February 13, 2020
- MHLW Calls for Stable Supplies of HIV Drugs amid Coronavirus Outbreak
February 13, 2020
- PMDA to Set Up New Consultation Services for Continuous Manufacturing, Database Use
February 12, 2020
- MHLW Urges Pharmacies to Limit Per-Customer Purchases for Face Masks, Sanitizer
February 12, 2020
- Chuikyo Issues Recommendation for 2020 Reimbursement Reform; Biosimilar Premium Set at 1,500 Yen per Month
February 10, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…